Neil Almstead, who serves as the Chief Technical Operations Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), has completed a significant divestiture of company equity. Between June 24 and June 25, 2026, Almstead sold 26,283 shares of common stock, realizing a total value of approximately $2.25 million. These sales were executed under the framework of a pre-arranged Rule 10b5-1 trading plan, which the executive originally adopted on November 11, 2025. This structured approach to selling ensures compliance with securities regulations while allowing for the liquidation of equity holdings.
The financial mechanics of the transaction reveal a complex interplay of option exercises and subsequent sales. Prior to the sale, Almstead acquired an identical number of 26,283 shares through the exercise of stock options on the same dates. The acquisition cost for these shares ranged from $38.10 to $39.42 per share, totaling $1,001,514. The majority of these options were exercisable at $38.10 per share, with an expiration date of January 6, 2032. A smaller tranche of 100 shares was exercised at $39.42 per share, stemming from an option granted on January 5, 2023, which vests over a four-year period and expires on January 4, 2033. The shares sold were fetched at prices between $85.01 and $87.00 per share, accumulating to a total of $2,254,463.
Following these transactions, Almstead's direct ownership in PTC Therapeutics stands at 60,137 shares. The timing of these sales is particularly noteworthy given the recent performance of PTCT shares. The stock has surged over 70% in the past year and is currently trading near its 52-week high of $87.50. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. For investors seeking deeper insights, InvestingPro offers 11 additional ProTips and comprehensive Pro Research Reports covering PTCT and 1,400+ other US equities.
In other recent news, PTC Therapeutics reported impressive earnings for the first quarter of 2026, surpassing analyst expectations. The company achieved an earnings per share of -$0.03, significantly better than the projected -$0.46, and reported revenues of $273 million, exceeding the anticipated $224.08 million. In addition to strong earnings, PTC Therapeutics received several analyst upgrades. Jefferies upgraded the stock to Buy from Hold, citing optimistic projections for Sephience's revenue exceeding consensus expectations. TD Cowen also upgraded PTC Therapeutics to Buy, noting the company's progress in streamlining operations and strengthening its balance sheet. BofA Securities reiterated its Buy rating, highlighting the momentum of the Sephience launch and the potential for more than $2 billion in global peak sales. These recent developments reflect a positive outlook among analysts for PTC Therapeutics' future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.